West Nile Virus-Neutralizing Plasma for West Nile Virus Disease - PubMed
4 hours ago
- #West Nile Virus
- #Clinical Trial
- #Plasma Therapy
- Israel faced a major West Nile virus (WNV) outbreak in 2024.
- A randomized, double-blind, placebo-controlled trial evaluated WNV-neutralizing plasma for hospitalized patients.
- Participants were aged 60+ or 18-59 and immunocompromised, assigned 2:1 to plasma or placebo.
- Primary outcome: composite of all-cause mortality and functional deterioration at 30 days.
- No significant difference in primary outcome between treatment (50%) and placebo (50%) groups.
- Lower mortality in the treatment group (2/22) vs. placebo (4/12).
- Treatment associated with higher functional capacity and cognitive scores at 30 days.
- One allergic reaction observed in the treatment group.
- Conclusion: No reduction in death or functional deterioration, but improved cognitive and functional outcomes.